Terms: = Endocrine gland cancer AND ATP1A1, P05023, MGC51750, MGC3285, ENSG00000163399, 476 AND Clinical Outcome
4 results:
1. Pathogenesis of Primary Aldosteronism: Impact on clinical outcome.
Santana LS; Guimaraes AG; Almeida MQ
Front Endocrinol (Lausanne); 2022; 13():927669. PubMed ID: 35813615
[TBL] [Abstract] [Full Text] [Related]
2. The impact of diabetes mellitus on clinical outcomes following chemotherapy for the patients with pancreatic cancer: a meta-analysis.
Ma J; Wang J; Ge L; Long B; Zhang J
Acta Diabetol; 2019 Oct; 56(10):1103-1111. PubMed ID: 31069497
[TBL] [Abstract] [Full Text] [Related]
3. [Application of ATP-tumor chemosensitivity assay in recurrent epithelial ovarian cancer].
Zhao D; Wu LY; Li XG; Wang XB; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Zhang W
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):855-8. PubMed ID: 21223693
[TBL] [Abstract] [Full Text] [Related]
4. Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies.
de Graeff P; Hall J; Crijns AP; de Bock GH; Paul J; Oien KA; ten Hoor KA; de Jong S; Hollema H; Bartlett JM; Brown R; van der Zee AG
Br J Cancer; 2006 Sep; 95(5):627-33. PubMed ID: 16880779
[TBL] [Abstract] [Full Text] [Related]
